Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

462.90 -0.09 (-0.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

69 70 Next >

Markets Steady, Positive; Q4 Earnings Keep Rolling ↗

February 10, 2025

Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline...

Via Talk Markets

Topics Government Stocks / Equities World Trade

Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript ↗

February 10, 2025

VRTX earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Vertex's Revenue Surges but EPS Slips ↗

February 10, 2025

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Via The Motley Fool

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates

February 10, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the...

Via StockStory

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

February 04, 2025

Via Benzinga

Vertex Pharmaceuticals Unusual Options Activity ↗

February 03, 2025

Via Benzinga

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

February 10, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge? ↗

February 10, 2025

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth potential. Stock has bullish technicals but risks remain.

Via Benzinga

Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings ↗

February 10, 2025

Via Benzinga

US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst ↗

February 10, 2025

U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.

Via Benzinga

Topics World Trade

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday ↗

February 10, 2025

Stock futures up, focus on McDonald's, ON Semiconductor, VOXX, Rockwell Automation, Vertex Pharmaceuticals.

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in February ↗

February 09, 2025

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For

February 09, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Via StockStory

UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades' ↗

February 06, 2025

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Via Benzinga

Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now? ↗

February 04, 2025

Via The Motley Fool

3 Magnificent Stocks to Buy and Hold Forever ↗

February 03, 2025

Via The Motley Fool

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? ↗

February 02, 2025

Via The Motley Fool

What You Missed On Friday ↗

February 02, 2025

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

Topics Stocks / Equities

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗

February 02, 2025

Via The Motley Fool

Small- To Mid-Cap Biotech Trades Poised For Gains ↗

February 01, 2025

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...

Via Talk Markets

Topics ETFs Stocks / Equities

FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief ↗

January 31, 2025

FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.

Via Benzinga

Topics Cannabis

What's going on in today's session: S&P500 movers ↗

January 31, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Top S&P500 movers in Friday's session ↗

January 31, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Vertex Pharmaceuticals Stock Soars As Non-Opioid Pain Treatment Gets FDA Nod ↗

January 31, 2025

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain.

Via Talk Markets

Topics Stocks / Equities

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter ↗

January 31, 2025

The company won Food and Drug Administration approval for its non-opioid painkiller pill on Thursday.

Via Investor's Business Daily

Vertex Pharmaceuticals Shares Are Up Today: What's Going On? ↗

January 31, 2025

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy.

Via Benzinga

Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday ↗

January 31, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

January 31, 2025

From Vertex Pharmaceuticals

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.